FindTrial
Sign In

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04499755
Enrollment
100
Registered
2020-08-05
Start date
2020-06-01
Completion date
2030-12-10
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries

Brief summary

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

Detailed description

The study aims to study the Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

Interventions

DRUGNucleo CMP Forte

Nucleo CMP Forte twice daily for 6 weeks

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children with traumatic brain injury: Moderate and Severe.

Exclusion criteria

* Underlying CNS disorders,

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with improved glasgow coma score2 monthsThe number of patients with improved glasgow coma score

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026